We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Stago Launches New My Qualiris QC Website for Brand-New User Experience

By LabMedica International staff writers
Posted on 28 Jan 2022

Image: My Qualiris QC (Photo courtesy of Stago)

Image: My Qualiris QC (Photo courtesy of Stago)

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.

My Qualiris QC provides an easy-to-use and comprehensive External Quality Assessment service that will meet the daily and special coagulation testing needs of laboratories. To optimize the quality approach of laboratories, Stago had introduced the My Qualiris QC program more than 10 years ago. Built on Stago's expertise in hemostasis, My Qualiris QC carries out complete comparisons designed in accordance to the NF EN ISO/IEC 17043 standard to ensure reliability of results.

My Qualiris QC estimates global performance through an extensive multi-level comparison to ensure system accuracy. Stago’s color-coded reports and alerts are easy to interpret, and they include haemostasis-specific indicators. The new My Qualiris QC website allows laboratories to manage different user profiles, submit results and consult the available reports whenever they want. The dedicated, secured, multilingual website also allows laboratories to archive their results for five years and download their participation certificate for audits.

Related Links:
Stago: My Qualiris QC

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

Gold Member

Aspiration System

VACUSAFE

Clinical Informatics Platform

CLARION™

Automatic CLIA Analyzer

Shine i6000

Latest Hematology News

Channels

Clinical Chemistry

view channel

Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease

Liver disease can progress silently until treatment options become more limited. Routine blood panels measure markers such as cholesterol, bilirubin, and triglycerides but typically do not include bile... Read more

Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease

Chronic kidney disease (CKD) is a major cause of mortality worldwide and often progresses silently until advanced stages. Despite the availability of simple urine and blood tests, many cases remain undetected,... Read more

Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes

Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read more

Molecular Diagnostics

view channel

Image: Incorporating the score into routine testing could help genetic laboratories diagnose type 1 diabetes in patients with unexplained negative MODY results (Image Credit: Adobe Stock)

Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing

Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more

Self-Collected HPV Testing Reaches Patients Missed by Routine Screening

Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more

Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more

Immunology

view channel

Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis

Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more

Image: The findings highlight the potential of blood-based immune profiling to provide a more comprehensive picture of how patients respond to immunotherapy. (Image Credit: Adobe Stock)

Immune Cell Blood Test May Predict Melanoma Immunotherapy Response

Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more

Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury

Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel

Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs

Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more

Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.

Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more

Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections

Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read more

Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more

Pathology

view channel

Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more

Image: Graphical Abstract (Zhijie Liu et al, Ultrarapid deep 3D histology enables intraoperative mapping of glioma infiltration, Cell (2026). DOI: 10.1016/j.cell.2026.07.026)

30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment

Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read more

AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals

Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read more

Image: The fine-tuned model predicted seven outputs using whole slide images (WSIs). (Abadh K. Chaurasia et al, The American Journal of Pathology (2026). DOI: 10.1016/j.ajpath.2026.05.008)

AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers

Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more

Technology

view channel

Autonomous Robotic System Receives FDA Authorization for Blood Collection

Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more

Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results

Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

New CE-Certified Software Advances Whole-Genome Cancer Testing

European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more

Industry

view channel

AI-Powered Pathology Collaboration Supports Companion Diagnostic Development

Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more

Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics

CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more

Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis

Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more

Image: Professor David Brettle, Chief Scientific Officer at Leeds Teaching Hospitals NHS Trust with a pathology slide showing the TANGO technology (Photo courtesy of Leeds Teaching Hospitals NHS Trust)

Standardized Staining Technology Advances Digital Pathology Workflows

Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more